Biosimilar Naming Reg Could Pit FDA Against WHO
This article was originally published in PharmAsia News
The US FDA has said that a suffix has to be attached to biosimilar names to ‘help us,’ underscoring fundamental differences in agencies’ philosophies for adding a four-letter code.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.
Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions written record; negotiations for BsUFA III may be opportunity to create such a process.
CDER director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.